Customise Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorised as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

For more information on how Google's third-party cookies operate and handle your data, see: Google Privacy Policy

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyse the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customised advertisements based on the pages you visited previously and to analyse the effectiveness of the ad campaigns.

Other uncategorised cookies are those that are being analysed and have not been classified into a category as yet.

No cookies to display.

PHARMASEAL Launches Engility® CTMS, an Innovative Clinical Trial Management Platform for Unified Governance­

PHARMASEAL Launches Engility® CTMS, an Innovative Clinical Trial Management Platform for Unified Governance­

January 22, 2019

Nottingham, UK – January 22, 2019: PHARMASEAL, a new provider of clinical trial management and governance solutions to enter the market, has launched Engility® CTMS, the first product to be released from its Engility B2B platform.

With a focus on usability and rapid implementation, this innovative new generation clinical trial management system (CTMS) has been designed to increase the level of governance and control that organisations demand from their management systems to enable effective oversight of their clinical trials.

A key challenge to overcome in the design was to optimise the cost of software validation so that new innovations can be introduced easily for the benefit of customers. Engility CTMS is engineered for change and benefits from extensive automation to deliver new features in a regulated industry, faster than current products. With an intuitive interface and a flexible cloud architecture, biopharmaceutical and medical device companies of all sizes can leverage affordable enterprise technology to fit their particular organisation model.

Commenting on the company’s introduction to the market and the launch of its foundation product Engility CTMS, Daljit Cheema, CEO and Founder of PHARMASEAL said:

“We are extremely proud to finally launch our new company and release our innovative CTMS product. Our collective passion for continuous innovation led to developing the Engility platform and our first product, Engility CTMS. With Engility, we can enable more companies to improve their governance and oversight processes. PHARMASEAL has proven that by applying advanced engineering and automation, technology can streamline and consolidate complex trial management activities. We are excited to introduce Engility to the world market.”

For further information, please visit www.pharmaseal.co or email info@pharmaseal.co

For all press enquiries please contact Sally Vernon via email sally@rockpigeon.co